Evidence map›Paper›PMID 26041551›Full record

ArticleHealth research policy and systems2015

Industry-sponsored clinical research outside high-income countries: an empirical analysis of registered clinical trials from 2006 to 2013.

Srinivas Murthy, Kenneth D Mandl, Florence T Bourgeois

Abstract readComparative Study
In one paragraph

Article in Health research policy and systems, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Srinivas MurthyDepartment of Pediatrics, University of British Columbia, 4500 Oak Street, V6H 3V4, Vancouver, BC, Canada. Srinivas.murthy@cw.bc.ca.
Kenneth D MandlCenter for Biomedical Informatics, Harvard Medical School, Boston, MA, USA. Kenneth.mandl@childrens.harvard.edu.
Florence T BourgeoisChildren's Hospital Informatics Program, Boston Children's Hospital, 320 Longwood Avenue, 02115-5737, Boston, MA, USA. florence.bourgeois@childrens.harvard.edu.

Funding

EXCLUSION OF OLDER PATIENTS IN CLINICAL DRUG TRIALSR21AG043715 · NIA · BOSTON CHILDREN'S HOSPITAL · PI BOURGEOIS, FLORENCE, MANDL, KENNETH D. · 2013 to 2014
$494k
NIA NIH HHS R21 AG043715NIA NIH HHS R21AG043715-01A1
6 · The paper itself

Abstract

backgroundIndustry-sponsored clinical trials, in the past performed almost exclusively in more developed countries, now often recruit participants globally. However, recruitment from outside high-income countries may not represent the ultimate target population for the intervention. Clinical trial registries provide an opportunity to quantify and examine the type of clinical research performed in various geographic regions. We sought to characterize industry-sponsored randomized controlled trials conducted in high-income countries and to compare these trials to those performed outside high-income countries.

methodsClinical trial data on all industry-funded randomized controlled trials conducted between 2006 and 2014 were obtained from the registry ClinicalTrials.gov. Trials were classified according to their study sites as conducted in high or non-high income countries, and data on trial characteristics were collected.

resultsOf 22,511 relevant trials, a total of 6,085 (27.0 %) trials included study sites outside a high-income country, and 2,045 (9.1 %) were conducted exclusively outside high-income countries. Of country groups, Central Europe had the greatest number of trials (3,127), followed by Eastern Europe (2,075). The percentage of trials with study sites outside high-income countries remained relatively constant over the study period. Studies with sites outside high-income countries tended to recruit more participants (median enrolled participants 265 vs. 71, P <0.001), to be longer (median study duration 20 vs. 13 months, P <0.05), and to study more advanced phase interventions (Phase 3 or 4 trial 58 % vs. 33 %, P <0.001).

conclusionsMore than a quarter of industry-sponsored trials include participants from outside high-income countries and this rate remained stable over the 7-year study period. Trials conducted outside high-income countries tend to be larger, have a longer duration, and study later phase interventions compared to studies performed exclusively in high-income countries.

Indexed as

Biomedical ResearchDeveloping CountriesPatient SelectionResearch SubjectsDrug IndustryEuropeHumansIncomeRandomized Controlled Trials as TopicRegistriesResearch Support as Topic

Identifiers

PMID26041551
PMCPMC4465475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.